(Q38223050)

31 August 2017

Intranasal formulations: promising strategy to deliver vaccines (English)

1 reference

31 August 2017

2

Priya Sakthivel

0 references

author name string

Peggy Riese

series ordinal

1

1 reference

31 August 2017

Stephanie Trittel

series ordinal

3

1 reference

31 August 2017

Carlos A Guzmán

series ordinal

4

1 reference

31 August 2017

language of work or name

English

0 references

publication date

25 June 2014

1 reference

Expert Opinion on Drug Delivery

31 August 2017

1 reference

31 August 2017

11

1 reference

31 August 2017

10

1 reference

31 August 2017

1619-1634

1 reference

Edward jenner and the small pox vaccine

31 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

The biology of oral tolerance and issues related to oral vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Intranasal delivery of antiviral siRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Nasal delivery of human growth hormone: in vitro and in vivo evaluation of a thiomer/glutathione microparticulate delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Pathophysiology of allergic and nonallergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

The crucial role of dendritic cells in rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Mucosal vaccines: the promise and the challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Immune functions of nasopharyngeal lymphoid tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Strategies for intranasal delivery of vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Antigen targeting to M cells for enhancing the efficacy of mucosal vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Enhancing oral vaccine potency by targeting intestinal M cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

M cell-targeted mucosal vaccine strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Inside the mucosal immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Mucosal vaccine design and delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Live attenuated influenza vaccine (FluMist®; Fluenz™): a review of its use in the prevention of seasonal influenza in children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

A pandemic influenza vaccine in India: from strain to sale within 12 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

A post-marketing surveillance study of a human live-virus pandemic influenza A (H1N1) vaccine (Nasovac (®) ) in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Differential serum cytokine responses to inactivated and live attenuated seasonal influenza vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Risk of presentation to hospital with epileptic seizures after vaccination with monovalent AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine (Pandemrix): self controlled case series study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Evaluation of in vitro cross-reactivity to avian H5N1 and pandemic H1N1 2009 influenza following prime boost regimens of seasonal influenza vaccination in healthy human subjects: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

The safety and effectiveness of self-administration of intranasal live attenuated influenza vaccine in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

A phase I clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Norovirus vaccine against experimental human Norwalk Virus illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Intranasal vaccination with an adjuvanted Norwalk virus-like particle vaccine elicits antigen-specific B memory responses in human adult volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Vaccine adjuvants: key tools for innovative vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Evaluation of TLR agonists as potential mucosal adjuvants for HIV gp140 and tetanus toxoid in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Stimulation of toll-like receptor 2 with bleomycin results in cellular activation and secretion of pro-inflammatory cytokines and chemokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

TLR-based immune adjuvants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Modulating vaccine responses with dendritic cells and Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Intranasal vaccination promotes detrimental Th17-mediated immunity against influenza infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Evaluation of an intranasal virosomal vaccine against respiratory syncytial virus in mice: effect of TLR2 and NOD2 ligands on induction of systemic and mucosal immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Prime-boost immunization with cruzipain co-administered with MALP-2 triggers a protective immune response able to decrease parasite burden and tissue injury in an experimental Trypanosoma cruzi infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Outer membrane vesicles of Porphyromonas gingivalis elicit a mucosal immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Gold nanoparticle-M2e conjugate coformulated with CpG induces protective immunity against influenza A virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Intranasal but not intravenous delivery of the adjuvant α-galactosylceramide permits repeated stimulation of natural killer T cells in the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

A pegylated derivative of alpha-galactosylceramide exhibits improved biological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Intranasal immunization promotes th17 immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

NKT cell stimulation with α-galactosylceramide results in a block of Th17 differentiation after intranasal immunization in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Intranasal immunization with pneumococcal conjugate vaccines with LT-K63, a nontoxic mutant of heat-Labile enterotoxin, as adjuvant rapidly induces protective immunity against lethal pneumococcal infections in neonatal mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Regulation of cellulose synthesis in Acetobacter xylinum by cyclic diguanylic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Bis-(3',5')-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

STING and the innate immune response to nucleic acids in the cytosol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Cyclic di-GMP stimulates protective innate immunity in bacterial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Activation and regulation of the inflammasomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Synthesis, characterization and evaluation of novel triblock copolymer based nanoparticles for vaccine delivery against hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Chitosan modification and pharmaceutical/biomedical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Chitosan-based delivery systems for mucosal vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Evaluation of the effectiveness and safety of chitosan derivatives as adjuvants for intranasal vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Effect of chitosan on epithelial permeability and structure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

In vivo induction of mucosal immune responses by intranasal administration of chitosan microspheres containing Bordetella bronchiseptica DNT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Co-delivery of viral proteins and a TLR7 agonist from polysaccharide nanocapsules: a needle-free vaccination strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Coadministration of polyinosinic:polycytidylic acid and immunostimulatory complexes modifies antigen processing in dendritic cell subsets and enhances HIV gag-specific T cell immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Liposome-based delivery system for vaccine candidates: constructing an effective formulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Effect of lipopolysaccharide on intranasal administration of liposomal Newcastle disease virus vaccine to SPF chickens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

The virosome concept for influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Influenza virosomes as vaccine adjuvant and carrier system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Immunostimulating complexes (ISCOMs) for nasal vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Mucosal Immune System and M Cell-targeting Strategies for Oral Mucosal Vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

M cells expressing the complement C5a receptor are efficient targets for mucosal vaccine delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

M cell targeting by a Claudin 4 targeting peptide can enhance mucosal IgA responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

Immune exclusion is a function of IgA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2014.931936

10.1517/17425247.2014.931936

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference